• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Genmab A/S

    11/14/25 12:26:59 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GMAB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    GENMAB A/S

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    K3967W102

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    K3967W102


    1Names of Reporting Persons

    ORBIS INVESTMENT MANAGEMENT LTD
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    Unknown
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,726,799.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,726,799.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,726,799.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    K3967W102


    1Names of Reporting Persons

    Allan Gray Australia Pty Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    AUSTRALIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,932.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,932.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,932.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    GENMAB A/S
    (b)Address of issuer's principal executive offices:

    TOLDBODGADE 33, Copenhagen, DENMARK 1253
    Item 2. 
    (a)Name of person filing:

    ORBIS INVESTMENT MANAGEMENT LTD Allan Gray Australia Pty Ltd
    (b)Address or principal business office or, if none, residence:

    ORBIS INVESTMENT MANAGEMENT LTD: Orbis House, 25 Front Street, Hamilton, Bermuda HM11 Allan Gray Australia Pty Ltd: Level 2, Challis House, 4 Martin Place, Sydney NSW2000, Australia
    (c)Citizenship:

    ORBIS INVESTMENT MANAGEMENT LTD - UNKNOWN Allan Gray Australia Pty Ltd - AUSTRALIA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    K3967W102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Equivalent to an IA.
    Item 4.Ownership
    (a)Amount beneficially owned:

    3,732,731 Orbis Investment Management Ltd owns 2,620,635 Common Stock and 11,061,638 American Depositary Receipts representing 1,106,164 Common Stock Allan Gray Australia Pty Ltd owns 4,295 Common Stock and 16,368 American Depositary Receipts representing 1,637 Common Stock
    (b)Percent of class:

    5.8  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    ORBIS INVESTMENT MANAGEMENT LTD - 3,726,799 Allan Gray Australia Pty Ltd - 5,932

     (ii) Shared power to vote or to direct the vote:

    ORBIS INVESTMENT MANAGEMENT LTD - 0 Allan Gray Australia Pty Ltd - 0

     (iii) Sole power to dispose or to direct the disposition of:

    ORBIS INVESTMENT MANAGEMENT LTD - 3,726,799 Allan Gray Australia Pty Ltd - 5,932

     (iv) Shared power to dispose or to direct the disposition of:

    ORBIS INVESTMENT MANAGEMENT LTD - 0 Allan Gray Australia Pty Ltd - 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Other persons have the right to receive dividends from, the power to direct the receipt of dividends from, or the right to receive the proceeds from the sale of, the securities of the issuer identified in Item 4(a) that are beneficially owned by Orbis Investment Management Ltd. Another person has the right to receive dividends from, the power to direct the receipt of dividends from, or the right to receive the proceeds from the sale of, the securities of the issuer identified in Item 4(a) that are beneficially owned by Allan Gray Australia Pty Ltd.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Information with respect to each of Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd (collectively, the "Reporting Persons") is given solely by each such Reporting Person and no Reporting Person has responsibility for the accuracy or completeness of information supplied by any other Reporting Person. Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd are classified as a Non-U.S. Institution (FI) that is equivalent to an Investment Adviser (IA). Notwithstanding that the Reporting Persons are making this filing together, none of the Reporting Persons represents that it is a member of a group for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended. Each Reporting Person disclaims beneficial ownership of any shares beneficially owned by any other Reporting Person as specified in Item 4(a).
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    ORBIS INVESTMENT MANAGEMENT LTD
     
    Signature:Matthew Gaarder
    Name/Title:Attorney-in-Fact
    Date:11/14/2025
     
    Allan Gray Australia Pty Ltd
     
    Signature:Matthew Gaarder
    Name/Title:Attorney-in-Fact
    Date:11/14/2025
    Exhibit Information

    POWER OF ATTORNEY THIS DEED OF POWER OF ATTORNEY is made on this the 6 day of June 2019. The undersigned, Orbis Investment Management Limited, a limited company duly organized under the laws of Bermuda with its registered office at Orbis House, 25 Front Street, Hamilton, HMI 1, Bermuda the "Company"), does hereby make, constitute and appoint each of Ali Ziai, David Gasperow, Elizabeth Lee, Eugene Tan, Hugh Gillespie, Ian Noetzel, James Dorr, Katharine Summerley, Matthew Gaarder, Michael Fox, Samantha Scott, and Tim Freeman acting severally, as its true and lawful attorneys-in-fact, for the purpose of from time to time executing in its name and on its behalf, whether the Company individually or as representative of others, any and all certificates, documents, filings, forms, instruments, schedules, statements, and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership and/or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including without limitation Forms 3, 4, 5, 13F, and 13H and Schedules 13D and 13G and any amendments to any of the foregoing as may be required to be filed with the U.S. Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates or subsidiaries. This power of attorney and any dispute or claim arising out of or in connection with it, its subject matter or its formation shall be governed by and construed in accordance with the law of Bermuda. IN WITNESS WHEREOF this power of attorney has been duly executed and delivered for and on behalf of the Company as a deed and takes effect on the date stated at the beginning of it. EXECUTED and DELIVERED as a DEED For and on behalf of ORBIS INVESTMENT MANAGEMENT LIMITED By: /s/ Matthew Furr Name: Matthew Furr Title: Director in the presence of: By: /s/ Daniel Samilski Witness signature Name: Daniel Samilski Address: Orbis House, 25 Front St, Hamilton HM 11, Bermuda Occupation: Compliance Manager POWER OF ATTORNEY This DEED OF POWER OF ATTORNEY is made on this the 6th day of June 2019. The undersigned, Allan Gray Australia Pty Limited, a proprietary company duly organized under the laws of Australia with its registered office at Level 2, Challis House, 4-10 Martin Place, Sydney NSW2000, Australia (the "Company"), does hereby make, constitute and appoint each of Ali Ziai, David Gasperow, Elizabeth Lee, Eugene Tan, Hugh Gillespie, Ian Noetzel, James Dorr, Katharine Summerley, Matthew Gaarder, Michael Fox, Samantha Scott, and Tim Freeman acting severally, as its true and lawful attorneys-in-fact, for the purpose of from time to time executing in its name and on its behalf, whether the Company individually or as representative of others, any and all certificates, documents, filings, fo1ms, instruments, schedules, statements, and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership and/or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including without limitation Fo1ms 3, 4, 5, 13F, and 13H and Schedules 13D and 13G and any amendments to any of the foregoing as may be required to be filed with the U.S. Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company, an affiliate or subsidiary of the Company, or an affiliate or subsidiary of Orbis Allan Gray Limited. This power of attorney and any dispute or claim arising out of or in connection with it, its subject matter or its formation shall be governed by and construed in accordance with the law of Australia. IN WITNESS WHEREOF this power of attorney has been duly executed and delivered for and on behalf of the Company as a deed and takes effect on the date stated at the beginning of it. EXECUTED and DELIVERED as a DEED For and on behalf of ALLAN GRAY AUSTRALIA PTY LIMITED By: /s/ Hugh Gillespie Name: Hugh Gillespie Title: Director in the presence of: By: /s/ Erika Mattatall Witness signature Name: Erika Mattatall Address: Orbis House, 25 Front St, Hamilton HM 11, Bermuda Occupation: Administrative Assistant

    Get the next $GMAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GMAB

    DatePrice TargetRatingAnalyst
    9/23/2025$43.00Neutral → Buy
    Guggenheim
    4/1/2025Mkt Perform → Underperform
    Bernstein
    3/11/2025Mkt Perform → Outperform
    William Blair
    2/13/2025$27.00Market Perform → Outperform
    Leerink Partners
    10/8/2024Buy
    Redburn Atlantic
    9/4/2024$31.00Equal-Weight
    Morgan Stanley
    8/20/2024Overweight → Neutral
    JP Morgan
    7/15/2024Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $GMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

    Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line setting In the Phase 3 EPCORE® FL-1 trial, fixed duration EPKINLY + R2 demonstrated significantly superior progression-free survival and overall response rates compared to standard of care R2, with approximately three out of four patients achieving a complete response This approval marks the third indication for EPKINLY and the first-ever FDA approval for a bispecific combination therapy in the lymphoma space Genmab A/S (NASDAQ:GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination

    11/18/25 11:30:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

    Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line settingIn the Phase 3 EPCORE® FL-1 trial, fixed duration EPKINLY + R2 demonstrated significantly superior progression-free survival and overall response rates compared to standard of care R2, with approximately three out of four patients achieving a complete responseThis approval marks the third indication for EPKINLY and the first-ever FDA approval for a bispecific combination therapy in the lymphoma space COPENHAGEN, Denmark; November 18, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that EPKINLY® (epco

    11/18/25 11:30:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

    More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of B-cell malignancies New data demonstrate potential of epcoritamab in first and second-line settings in follicular lymphoma (FL) and first-line in diffuse large B-cell lymphoma (DLBCL) Results from Phase 3 EPCORE FL-1 trial, evaluating epcoritamab in combination with rituximab and lenalidomide (R2) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) accepted for oral presentation Genmab A/S (NASDAQ:GMAB) today announced that more than 20 abstracts ev

    11/3/25 9:05:00 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    SEC Filings

    View All

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    11/18/25 3:04:05 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genmab A/S

    6-K - GENMAB A/S (0001434265) (Filer)

    11/18/25 12:10:26 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Genmab A/S

    SCHEDULE 13G - GENMAB A/S (0001434265) (Subject)

    11/14/25 12:26:59 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Genmab upgraded by Guggenheim with a new price target

    Guggenheim upgraded Genmab from Neutral to Buy and set a new price target of $43.00

    9/23/25 7:47:11 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab downgraded by Bernstein

    Bernstein downgraded Genmab from Mkt Perform to Underperform

    4/1/25 9:01:35 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab upgraded by William Blair

    William Blair upgraded Genmab from Mkt Perform to Outperform

    3/11/25 7:35:51 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Genmab A/S (Amendment)

    SC 13G/A - GENMAB A/S (0001434265) (Subject)

    2/8/24 10:03:08 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Genmab A/S (Amendment)

    SC 13G/A - GENMAB A/S (0001434265) (Subject)

    2/2/24 2:18:06 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genmab A/S

    SC 13G - GENMAB A/S (0001434265) (Subject)

    2/6/23 2:36:15 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

    Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera

    2/22/21 8:00:51 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GMAB
    Financials

    Live finance-specific insights

    View All

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st

    9/29/25 1:14:00 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus,

    9/29/25 1:08:26 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capital Increase in Genmab as a Result of Employee Warrant Exercise

    Company Announcement COPENHAGEN, Denmark; August 12, 2025 – Genmab A/S (NASDAQ:GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,580 shares at DKK 1,025.00,1,874 shares at DKK 1,050.00, and109 shares at DKK 1,161.00. Proceeds to the company are approximately DKK 4.7 million. The increase corresponds to approximately 0.01% of the company's share capital. The new shares are ordinary shares without any special rights and are freely tra

    8/12/25 2:36:02 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care